Sponsor
Jefferson Van Drew
Representative · R-NJ
Representative · R-NJ
The bill offers potentially large reductions in U.S. drug list prices and public spending via international price caps and greater transparency, but risks reduced drug availability, manufacturer responses that shift costs or slow innovation, pricing distortions if foreign list prices misrepresent net costs, and significant enforcement burdens.
People who pay for prescription drugs — including insured and uninsured patients and those with chronic conditions — could see lower U.S. list prices because prices would be capped at the average of six high‑income countries.
Medicare, Medicaid, and other purchasers could pay less for covered drugs, reducing federal and state program spending and lowering out‑of‑pocket costs for beneficiaries.
Manufacturers would be required to report annually, increasing price transparency and helping regulators, payers, and consumers compare U.S. and international prices.
Patients with chronic conditions and health systems could face reduced or delayed U.S. availability of high‑priced medicines if manufacturers choose not to launch or withdraw products from the U.S. market.
Manufacturers might respond by raising list prices for other drugs, shifting costs to non‑covered products, or cutting R&D investment, which could raise costs elsewhere and slow new drug development.
If caps are based on foreign 'list prices' that don't reflect confidential discounts or rebates, the policy could mismeasure true net prices and distort U.S. pricing and payer negotiations.
Based on analysis of 2 sections of legislative text.
Caps U.S. retail list prices for covered drugs/biologics at the annual average retail list price across Canada, France, Germany, Italy, Japan, and the UK, with reporting requirements and civil penalties for noncompliance.
Official title: To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.
Introduced May 13, 2025 by Jefferson Van Drew · Last progress May 13, 2025
Requires the HHS Secretary to cap U.S. retail list prices for approved drugs and biologicals at no more than the annual average retail list price across Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must report U.S. and the listed-country list prices each year, the Secretary will calculate an annual international average and issue guidance, and manufacturers who price above the cap owe civil penalties equal to ten times the per-unit difference for each unit sold above the cap.